BioSpace News Archive

EpicentRx, Inc announced data from a Phase 2 randomized clinical trial of RRx-001 vs. regorafenib in patients with third/fourth line colorectal cancer has been selected for a poster presentation at the 2023 American Society of Clinical Oncology Gastrointestinal Cancers Symposium being held January 19-21 in San Francisco.

ADARx Pharmaceuticals, Inc., a clinical stage biotechnology company developing RNA-targeting therapeutics, today announced the dosing of the first cohort in a Phase 1 clinical study of ADX-324 for the treatment of hereditary angioedema (HAE).

On the journey from gene to protein, a nascent RNA molecule can be cut and joined, or spliced, in different ways before being translated into a protein.

Quest Diagnostics Incorporated (NYSE: DGX), the world’s leading provider of diagnostic information services, announced that it will report fourth quarter and full year 2022 financial results on Thursday, February 2, 2023, before the market opens.

Kerecis, the company pioneering the use of fish skin and fatty acids for tissue regeneration and protection, announced the release of two new products for the burn market, GraftGuide Mano™ and GraftGuide Micro™.

Drugmaker Eli Lilly & Co announced today that the FDA has issued a complete response letter, meaning it has not granted accelerated approval for amyloid-clearing antibody donanemab.

Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS) announced today that it has amended certain financial terms of the $20 million convertible note issued by its partner, Cytovia Therapeutics, LLC (“Cytovia”) in payment of the upfront collaboration consideration provided for pursuant to the research collaboration and non-exclusive license agreement between Cellectis and Cytovia.

The Board of Directors of Sensient Technologies Corporation has declared a regular quarterly cash dividend on its common stock of $0.41 per share.

Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) (“Defence” or the “Company”), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies,

Fresenius Medical Care, the world’s leading provider of products and services for individuals with renal diseases, has taken the Zero Health Gaps Pledge at the World Economic Forum in Davos, Switzerland.